Clinical trials: CYP3A4 Induction
- Condition CYP3A4 Induction
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Volunteers
A Study of LY2835219 in Healthy Participants
The aim of this two-period study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and when it is given as a single oral dose in combination with rifampin (a Food and Drug…
- Trial name
- NCT02256267
- Testing
- LY2835219, Rifampin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Fungal Infection
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
This is a Phase 1, open-label study to evaluate the drug-drug interaction potential of a strong CYP3A4 inhibitor (itraconazole) and a pan-CYP inducer (rifampin) on APX001 in two parallel groups of healthy subjects.
- Trial name
- NCT04166669
- Testing
- APX001, Itraconazole, Rifampin
- Where
- 2 sites in Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4
Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex
Study to assess the effect of rifampicin, ketoconazole and omeprazole on the pharmacokinetics of a single dose of Sativex and to evaluate the safety of Sativex when given in combination with these other drugs.
- Conditions
- Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor
- Trial name
- NCT01323465
- Testing
- Sativex and rifampicin, Sativex and ketoconazole, Sativex and omeprazole
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
P-glycoprotein, Healthy Volunteers
A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers
The purpose of this single-dose, open-label, sequential, three-period study in 15 healthy subjects was to assess the influence of P-glycoprotein inhibition and simultaneous CYP3A4 and P-glycoprotein induction on lenvatinib…
- Trial name
- NCT02199392
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Healthy Volunteers
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40.
- Trial name
- ABBV-576 DDI (NCT05530278)
- Testing
- Galicaftor, ABBV-576, Navocaftor
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Drug-drug Interaction
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
This study is being done to look at how tucatinib could affect the way other drugs work. This study will look at healthy volunteers and how tucatinib affects their liver enzymes.
- Trial name
- NCT03723395
- Testing
- tucatinib, itraconazole, rifampin
- Where
- 2 sites in United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Seagen Inc.
Urinary Tract Infections
Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years
The objective of this study is to determine the magnitude and clinical relevance of a potential drug-drug interaction of GSK3882347 with midazolam (MDZ) in healthy participants.
- Trial name
- NCT05760261
- Testing
- Midazolam, GSK3882347
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Biological Availability
Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction
Evaluate the effect of a probe CYP3A4 inhibitor and inducer on the pharmacokinetics of BAY1841788 (ODM-201)
- Trial name
- NCT03048110
- Testing
- BAY1841788 (ODM-201), Itraconazole, Rifampicin
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteers
A Study of Baricitinib and Rifampicin in Healthy Participants
The purposes of this study are to look at what effect multiple doses of rifampicin have on a single dose of baricitinib and to look at the safety and tolerability of these drugs. Side effects will be documented.
- Trial name
- NCT01910311
- Testing
- Baricitinib, Rifampicin
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults
The purpose of this study is to investigate the potential for cytochrome P450 (CYP) 3A4 induction after dosing with INDV-2000 via use of midazolam as a probe.
- Trial name
- NCT05694533
- Testing
- INDV-2000, Midazolam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Healthy
To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants
This study will evaluate the effects of nirogacestat 100 mg twice daily (BID) on the pharmacokinetics (PK) of a cytochrome P450 (CYP) cocktail.
- Trial name
- NCT07259330
- Testing
- Nirogacestat, Nirogacestat and Cocktail of CYP Specific Probe Substrates
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Endometriosis
Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan
This study will be conducted in a single center, open-label study with a single group fixed sequence design to evaluate the effect of repeated oral administration of 600 mg RIF(Rifampicin) given once daily over 11 days on the…
- Trial name
- NCT02975440
- Testing
- Rifampicin, Midazolam, BAY1002670_Vilaprisan
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Participants
Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
The purpose of the study is to assess the effects of multiple doses of itraconazole (a strong CYP3A4 inhibitor) on single dose PK of casdatifan in healthy adults and to assess the effects of multiple doses of phenytoin (a strong…
- Trial name
- NCT06919991
- Testing
- Casdatifan, Itraconazole, Phenytoin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Arcus Biosciences, Inc.
Healthy Volunteers
A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers
This study will evaluate the impact of CYP3A4 induction on the single-dose pharmacokinetics of ALKS 5461.
- Trial name
- NCT02545439
- Testing
- ALKS 5461
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Women, Contraception
Annovera™ Drug-Drug Interaction Study
A Drug-Drug Interaction (DDI) study to evaluate the effects of itraconazole and rifampin on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol from the Annovera Contraceptive Vaginal System (CVS)
- Trial name
- NCT04290390
- Testing
- Segesterone Acetate and Ethinyl Estradiol, Rifampin, Itraconazole
- Where
- Canada
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- TherapeuticsMD
Migraine
A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults
PF-05180999 is a novel phosphodiesterase-2 (PDE2) inhibitor. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of PF-05180999 administered twice daily over 14 days.
- Trial name
- NCT01981486
- Testing
- PF-05180999 Tablets
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects
The main purpose of this study is to determine the potential inhibitory/inducing effects of JNJ-54175446 after single and repeated dosing on the single-dose pharmacokinetics (PK) of a cocktail, containing selective probes of…
- Trial name
- NCT03058419
- Testing
- JNJ-54175446 150 mg, JNJ-54175446 600 mg, Midazolam 2 mg
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Drug Reactions
Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes
This study will help determine which types of drugs that may interact with Lu AF35700
- Trial name
- NCT03195946
- Testing
- Lu AF35700, Midazolam, Cocktail of CYP450 substrates
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Drug Interaction
Drug Interaction Study
This is a single center, 2-Part, Phase 1, open-label, fixed-sequence, drug-drug interaction study designed to compare the PK of ecopipam when administered alone and in combination with itraconazole (Part 1) or rifampicin (Part 2)…
- Trial name
- NCT06194864
- Testing
- Itraconazole, rifampicin, Ecopipam
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Emalex Biosciences Inc.
Drug-Drug Interaction (DDI), Healthy Subjects
A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men
This study evaluates how a drug that alters liver enzymes (rifampin) affects the metabolism of enzalutamide in men by measuring concentrations of enzalutamide and its metabolites in plasma.
- Conditions
- Drug-Drug Interaction (DDI), Healthy Subjects, Pharmacokinetics of Enzalutamide
- Trial name
- NCT02138799
- Testing
- enzalutamide, rifampin
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.